Issue link: https://www.e-digitaleditions.com/i/1543258
News about companies that support development of orally inhaled and nasal drug products (OINDPs), including regulatory approvals, new partnerships, new products and services, and results of clinical studies. 8 February 2026 Inhalation Cipla launches India's only inhaled insulin, Afrezza ® MUMBAI, INDIA—Cipla, Lim- ited announced the launch in India of Afrezza ® (insulin human) inhalation powder. e rapid- acting orally inhaled insulin is available in single-use cartridges and delivered by inhaler. Cipla had obtained regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) late in 2025 for the exclusive distribution and marketing of Afrezza, developed and marketed by MannKind Corporation of the United States. e inhaled alternative to daily prandial injec- tions is designed to support bet- ter adherence and enable quicker glycemic control for adults with type 1 and type 2 diabetes melli- tus. A company news release noted that Afrezza can help address emo- tional and practical barriers that often lead patients to delay or dis- continue insulin therapy. To sup- port insulin adherence, Cipla will also roll out a nationwide aware- ness initiative. e product is expected to benefit many of the 100 million adults in India cur- rently living with diabetes. neffy ® approved in China; first community use product for anaphylaxis SAN DIEGO, CALIFORNIA, U S — A R S P h a r m a c e u t i c a l s announced that the National Medical Products Administration (NMPA) in China has granted approval for neffy ® 2 mg (epineph- rine nasal spray) for the emergency treatment of Type 1 allergic reac- tions (anaphylaxis) in adults and children who weigh 30 kg or more. Pediatrix erapeutics, which has a license from ARS Pharma to market neffy in China, expects availability in the spring of 2026. Globe Newswire reported that cur- rently, there are no approved com- munity use epinephrine products in China, including auto-injectors, making neffy the first epinephrine Intertek expands capacity: New facility in Melbourn MELBOURN, UNITED KING- DOM—Intertek announced it is significantly expanding its Good Manufacturing Practice (GMP) pharmaceutical services with the acquisition of a 29,000 square foot facility in Melbourn, near Cam- bridge, United Kingdom. e expansion is a direct response to the rapid growth of its drug devel- opment programs and increas- ing client demand for support in inhaled biologics. Adjacent to Intertek's current facilities, the new building will increase manu- facturing and laboratory space to enhance the company's capabilities for inhaled and nasal drug devel- opment, including solid and liquid inhaled formulations, and focus on next-generation dry powder bio- pharmaceuticals as well as other drug delivery formats. e initial development phase of the new facility is scheduled to open in the second quarter of 2026, with addi- tional expansions planned from 2026 to 2028. Inhalation Sciences receives order from European university hospital H U D D I N G E , S W E D E N — According to Cision, Inhala- tion Sciences AB has secured a new inhalation research service (IRS) order for its PreciseInhale ® in vivo platform, which is designed to deliver controlled and high- precision inhalation exposures for preclinical research. e order will support advanced research using intratracheal exposure in rats and support in vivo studies to better understand the impact of inhaled compounds. e client is a lead- ing university hospital in Europe, known for pioneering research in oncology, transplantation, car- diovascular medicine and transla- tional sciences. e hospital treats more than 50,000 inpatients and 195,000 outpatients each year. INDUSTRY NEWS Proveris joins Investindustrial; will operate independently HUDSON, MASSACHUSETTS, US—Proveris Scientific announced it has been acquired by an indepen- dent subsidiary of Investindustrial, a European group of independently managed investment, holding and advisory companies with a history in the healthcare sector. Following the transaction, Proveris will con- tinue to operate as an independent company. With the new backing, Proveris is positioned to expand its capabilities and continue to support drug development across both small and large molecule programs. "e partnership with InvestIndustrial provides us with additional resources and capabil- ities to drive growth and support our customers success over the long term," said Dino Farina, Proveris CEO. "Our focus remains the same— supporting customers with high-quality science and reliable data—now with the additional resources of a committed long-term partner to guide the next phase of business development," added Chip Leveille, Proveris President. Chiesi submits carbon minimal inhaler to MHRA P A R M A , I TA LY — C h i e s i announced the submission of their carbon minimal pressurized metered dose inhaler (pMDI) containing beclometasone in 100 mcg and 200 mcg strengths to the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA), which occurred in December 2025. e submission is part of Chiesi's carbon minimal inhaler program, designed to reduce the environmental impact of pMDIs by transitioning to HFA-152a, a next-generation propellant. The program is expected to reduce the carbon footprint of Chiesi pMDIs by up to 90%. In addition, it aims to ensure a seamless transition for patients, combining therapeutic continuity and sustainability. continued on page 38